医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Döhler & IDC Host Shanghai Food Safety Federation

2016年12月06日 AM06:15
このエントリーをはてなブックマークに追加


 

SHANGHAI

On November 24th, The Döhler Group and International Dispensing Corporation (IDC) (IDND) hosted a visit to Döhler’s Asia-Pacific headquarters in Shanghai by President Gu Zhenhua and Secretary General Jiang Peizhen of the Shanghai Food Safety Federation.

The Federation is a liaison organization between Shanghai’s Food & Drug Administration and the country’s food and beverage companies. Accompanied by Roman Kupper, President of Döhler Asia Pacific, and Li Xin, IDC’s Industry Advisory Board member, the visitors toured Döhler’s R&D center and production line of Not-From-Concentrate (NFC) bag-in-box (BIB) juices equipped with IDC’s The Answer® aseptic tap.

In its widely circulated newsletter issued after the visit, the Shanghai Food Safety Federation declared that the Döhler NFC juice offering addressed “the healthy and natural trends in China” and that “The Answer® allows for safe dispensing of aseptic beverages at ambient temperatures while maintaining the sterility of the remaining contents for weeks.” In addition, the newsletter forecasted that, “… with China’s improvement of standard of living and consumer desire for better nutrition, demand [for the NFC product line]… would increase rapidly.”

Döhler has been successfully running its NFC BIB product line with The Answer® for over a year. Products include orange, apple, and mango juices, as well as coconut water.

The visit by Shanghai Food Safety Federation demonstrated the Federation’s influential efforts in collaborating with industry, as well as Döhler’s commitment to the China market through continued investment and innovation.

About The Döhler Group

Döhler (www.doehler.com) is a global producer, marketer, and provider of technology-based natural ingredients, ingredient systems, and integrated solutions for the food & beverage industry. Döhler’s integrated approach and the broad product portfolio are the optimal basis for innovation and safe food & beverage applications. The product portfolio ranges from flavors, colors, health and nutrition ingredients, cereal ingredients, dairy ingredients, specialty ingredients, fruit & vegetable ingredients to ingredient systems.

Headquartered in Darmstadt, Germany, Döhler is active in over 130 countries and has 26 production sites, as well as sales offices and application centers on every continent. More than 4,000 dedicated employees provide our customers with fully integrated food and beverage solutions from concept to realization. “WE BRING IDEAS TO LIFE,” briefly describes Döhler’s holistic, strategic, and entrepreneurial approach to innovation. This comprises market intelligence, trend monitoring, the developing of innovation products and product applications, advice on food safety and microbiology, food law as well as Sensory and Consumer Science.

For further information: Döhler GmbH Riedstrasse 7-9 64295 Darmstadt, Germany

About International Dispensing Corporation

IDC (www.idcinnovation.com) is a packaging research and development company that develops and manufactures breakthrough innovations for the food, beverage and packaging industries. IDC’s flagship product, The Answer®, the world’s only aseptic tap, can safely dispense both low and high acid aseptic liquids from a large-format flexible package (3-25 liters) while keep the remaining contents shelf-stable for weeks (in some case months) without refrigeration or preservatives. Targeting the developing world, which lacks refrigeration, IDC is driving projects with industry leaders in China, Pakistan, India, Africa, Turkey & the Middle East, Mexico & Latin America, and Europe, as well as the USA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161205006255/en/

CONTACT

IDC
Christopher Westwood, 212-464-7203
cwestwood@idcinnovation.com
or
The
Döhler Group
Diana Wolfsrädter
Phone +49 6151 306-1205
Fax
+49 6151 306-8205
diana.wolfstaedter@doehler.com

同じカテゴリーの記事 

  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究